Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Research analysts at Seaport Global Securities boosted their FY2017 earnings per share estimates for shares of Aurinia Pharmaceuticals in a report released on Wednesday, according to Zacks Investment Research. Seaport Global Securities analyst V. Bernardino now anticipates that the biotechnology company will post earnings of ($1.19) per share for the year, up from their previous forecast of ($1.21). Seaport Global Securities currently has a “Buy” rating and a $10.00 target price on the stock. Seaport Global Securities also issued estimates for Aurinia Pharmaceuticals’ Q4 2017 earnings at ($0.08) EPS, FY2019 earnings at ($0.19) EPS and FY2020 earnings at ($0.09) EPS.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. The firm’s revenue was up .0% compared to the same quarter last year.
A number of other equities analysts have also weighed in on the stock. Canaccord Genuity set a $11.00 price target on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 24th. Zacks Investment Research lowered shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 15th. Vetr upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.64 price target on the stock in a report on Wednesday, September 13th. Finally, Cantor Fitzgerald set a $14.00 target price on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. Aurinia Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $10.79.
Shares of Aurinia Pharmaceuticals (AUPH) traded down $0.13 on Friday, hitting $5.17. 653,525 shares of the stock were exchanged, compared to its average volume of 3,663,250. Aurinia Pharmaceuticals has a fifty-two week low of $2.02 and a fifty-two week high of $10.54.
Several institutional investors and hedge funds have recently made changes to their positions in AUPH. Bank of New York Mellon Corp acquired a new position in shares of Aurinia Pharmaceuticals during the 1st quarter worth $595,000. UBS Group AG boosted its holdings in shares of Aurinia Pharmaceuticals by 13.6% during the 1st quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock worth $824,000 after buying an additional 13,405 shares during the period. Morgan Stanley boosted its holdings in shares of Aurinia Pharmaceuticals by 11,061.7% during the 1st quarter. Morgan Stanley now owns 446,135 shares of the biotechnology company’s stock worth $3,273,000 after buying an additional 442,138 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter worth $776,000. Finally, Creative Planning boosted its holdings in shares of Aurinia Pharmaceuticals by 6,470.6% during the 2nd quarter. Creative Planning now owns 164,265 shares of the biotechnology company’s stock worth $1,007,000 after buying an additional 161,765 shares during the period. Institutional investors own 28.17% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Seaport Global Securities Weighs in on Aurinia Pharmaceuticals Inc’s FY2017 Earnings (AUPH)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/04/fy2017-earnings-forecast-for-aurinia-pharmaceuticals-inc-issued-by-seaport-global-securities-auph.html.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.